We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Gsk Plc | LSE:GSK | London | Ordinary Share | GB00BN7SWP63 | ORD 31 1/4P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 12.50 | 0.76% | 1,653.00 | 1,654.00 | 1,655.00 | 1,655.50 | 1,634.00 | 1,638.50 | 3,990,601 | 16:35:15 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 30.33B | 4.93B | 1.1970 | 13.83 | 68.14B |
From Apr 2019 to Apr 2024
By Ian Walker
GlaxoSmithKline PLC said Tuesday that it has formed a collaboration with Canadian biopharmaceutical company Medicago to develop a novel adjuvanted Covid-19 candidate vaccine.
The pharmaceutical giant said that phase 1 clinical testing will start in the middle of July and that the companies hope to have the vaccine ready for the first half of 2021. The companies also plan to use their technologies to develop vaccines for other infectious diseases.
The vaccine combines Medicago's recombinant coronavirus virus-like particles with Glaxo's pandemic adjuvant system. Coronavirus virus-like particles mimic the structure of the virus responsible for Covid-19, allowing them to be recognized by the immune system.
Write to Ian Walker at ian.walker@wsj.com
(END) Dow Jones Newswires
July 07, 2020 08:55 ET (12:55 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
1 Year Gsk Chart |
1 Month Gsk Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
